Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC
Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.
Yousef Zakharia, MD, medical oncologist, associate professor of medicine, the University of Iowa, the University of Iowa Hospitals and Clinics, discusses the real-world treatment outcomes of first-line axitinib (Inlyta) plus pembrolizumab (Keytruda) in patients with advanced renal cell carcinoma (RCC) based on International Metastatic RCC Database Consortium (IMDC) risk score.
Related Videos
Related Content
